Literature DB >> 16920899

Pediatric licensing status and the availability of suitable formulations for new medical entities approved in the United States between 1998 and 2002.

Komathi Balakrishnan1, Joanne Grieve, June Tordoff, Pauline Norris, David Reith.   

Abstract

The availability of new medical entities for children in the United States was examined at the time of marketing approval and 3 years later. New medical entities approved in the United States in each of the years 1998 to 2002 were identified using the Center for Drug Evaluation and Research Web site. Each Physicians' Desk Reference published in the years 1998 to 2005 was examined to determine formulations and licensing information. For the 133 new medical entities licensed to be marketed in the period 1998 to 2002, the number licensed for children increased from 5 (4%) to 39 (29%) in the 3 years after registration. After 3 years' marketing, 79 (59%) drugs were in formulations suitable for children, and 27 (20%) of the new medical entities were licensed and had a suitable formulation for children. Incentives to improve access for children to medicines should focus more on demonstration of improved access.

Entities:  

Mesh:

Year:  2006        PMID: 16920899     DOI: 10.1177/0091270006290509

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  9 in total

1.  Paediatric clinical pharmacology: at the beginning of a new era.

Authors:  Kalle Hoppu
Journal:  Eur J Clin Pharmacol       Date:  2007-10-31       Impact factor: 2.953

Review 2.  The EU's new paediatric medicines legislation: serving children's needs?

Authors:  Govin Permanand; Elias Mossialos; Martin McKee
Journal:  Arch Dis Child       Date:  2007-09       Impact factor: 3.791

3.  Access to prescribing information for paediatric medicines in the USA: post-modernization.

Authors:  Larissa Young; Francis Lawes; June Tordoff; Pauline Norris; David Reith
Journal:  Br J Clin Pharmacol       Date:  2008-12-10       Impact factor: 4.335

4.  The availability and age-appropriateness of medicines authorized for children in The Netherlands.

Authors:  Diana A van Riet-Nales; Karin E de Jager; Alfred F A M Schobben; Toine C G Egberts; Carin M A Rademaker
Journal:  Br J Clin Pharmacol       Date:  2011-09       Impact factor: 4.335

5.  Availability of pediatric-evaluated formulations in Serbia.

Authors:  Bojana Božić; Sanja Stupar; Duško Stupar; Uroš Babić; Milica Bajčetić
Journal:  Indian J Pharmacol       Date:  2017 Mar-Apr       Impact factor: 1.200

6.  Suitability of new drugs registered in Brazil from 2003 to 2013 for pediatric age groups.

Authors:  Jaqueline Cristina da Silveira Xavier E Castro; Stephanie Ferreira Botelho; Taisa Roberta Lopes Machado; Maria Auxiliadora Parreiras Martins; Liliana Batista Vieira; Adriano Max Moreira Reis
Journal:  Einstein (Sao Paulo)       Date:  2018-11-08

7.  Prioritising neonatal medicines research: UK Medicines for Children Research Network scoping survey.

Authors:  Mark A Turner; Sara Lewis; Daniel B Hawcutt; D Field
Journal:  BMC Pediatr       Date:  2009-08-12       Impact factor: 2.125

8.  Market failure and the poverty of new drugs in maternal health.

Authors:  Nicholas M Fisk; Rifat Atun
Journal:  PLoS Med       Date:  2008-01-22       Impact factor: 11.069

9.  A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.

Authors:  Ann Childress; Jeffrey Newcorn; Jeffrey G Stark; Russ McMahen; Mark Tengler; Carolyn Sikes
Journal:  J Child Adolesc Psychopharmacol       Date:  2016-05-26       Impact factor: 2.576

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.